Prestige Biologics Decides on 90 Billion KRW Paid-in Capital Increase

Prestige Biologics announced on the 12th that it has decided to conduct a paid-in capital increase through a third-party allotment to raise 89,926,340,000 KRW for debt repayment funds.

The number of new shares is 15,916,168 common shares.

The issue price per new share is 5,650 KRW, and the scheduled listing date of the new shares is the 25th of next month.

The third-party allotment target is Prestige Biopharma.